Elicio Therapeutics, Inc. — Director's Dealing 2021

Feb 12, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Angion Biomedica Corp. (ANGN)
CIK: 0001601485
Period of Report: 2021-02-09

Reporting Person: GANZI VICTOR F (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-02-09	Common Stock	C	18741	$11.57	Acquired	405405	Direct
2021-02-09	Common Stock	C	50122	$11.57	Acquired	455527	Direct
2021-02-09	Common Stock	X	367590	$6.43	Acquired	823117	Direct
2021-02-09	Common Stock	S	246720	$16	Disposed	576397	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-09	Convertible Promissory Note	$16	C		Disposed		Common Stock (216832.88)	Direct
2021-02-09	Convertible Promissory Note	$16	C		Disposed		Common Stock ()	Direct
2021-02-09	Warrant to Purchase Common Stock	$6.43	X	367590	Disposed	2028-07-05	Common Stock (367590)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	155581	Indirect

Footnotes

F1: Victor F. Ganzi 2012 GST Family Trust.

F2: On February 9, 2021 the Reporting Person exercised a warrant to purchase an aggregate of 614,310 shares of the Issuer's common stock for $16.00 a share, which represents the Issuer's IPO price. In connection with the automatic net exercise of the warrant immediately prior to the closing of the Issuer's IPO, the Issuer withheld 246,720 of the warrant shares to pay the exercise price and issued the remaining 367,590 shares of common stock to Reporting Person.

F3: The convertible promissory note converted immediately prior to the consummation of the IPO into Common Stock.

F4: The convertible promissory note ("Convertible Note") had a maturity date of May 28, 2021 and the principal amount of the Convertible Note converted upon the closing of the IPO into Common Shares at a conversion price equal to $18.00 per Common Share.

F5: The convertible promissory note ("Convertible Note") had a maturity date of August 21, 2021 and the principal amount of the Convertible Note converted upon the closing of the IPO into Common Shares at a conversion price equal to $18.00 per Common Share.